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Effect of Platelet-Rich Plasma
on the Healing of Intrabony Defects
Treated With an Anorganic Bovine Bone
Mineral: A Pilot Study
Ferenc Do¨ri,* Viola Kova´cs,* Nicole B. Arweiler,† Tama´s Husza´r,‡ Istva´n Gera,*
Dimitris Nikolidakis,§ and Anton Sculean§
Background: Periodontal therapy using the combination of platelet-rich
plasma (PRP) and different grafting materials has been suggested as a mo-
dality to enhance the outcome of regenerative surgery. In most clinical stud-
ies, a barrier membrane was used to cover the defects, and thus, the effects
of PRP may have been masked by the effects of the barrier. The data from
controlled clinical studies evaluating the effect of regenerative therapy us-
ing various grafting materials with or without PRP are still limited. The pur-
pose of this study was to clinically compare the healing of intrabony defects
treated with either a combination of an anorganic bovine bone mineral
(ABBM) and PRP to those obtained with ABBM alone.
Methods: Thirty patients with advanced chronic periodontal disease and
displaying one intrabony defect were randomly treated with PRP +ABBM or
ABBM alone. The following clinical parameters were evaluated at baseline
and 1 year after treatment: plaque index (PI), gingival index (GI), bleeding
on probing (BOP), probing depth (PD), gingival recession (GR), and clinical
attachment level (CAL). The primary outcome variable was CAL.
Results: No statistical significant differences in any of the investigated
parameters between the two groups were observed at baseline. Healing
was uneventful in all patients. In the PRP + ABBM group, mean PD de-
creased from 8.6 – 1.8 mm to 3.4 – 1.4 mm (P <0.001) and mean CAL
changed from 9.9 – 1.7 mm to 5.3 – 1.8 mm (P <0.001). In the ABBM group,
mean PD decreased from 8.5 – 2.0 mm to 3.2 – 1.3 mm (P <0.001) and
mean CAL changed from 9.6 – 1.9 mm to 4.9 – 1.5 mm (P <0.001). CAL
gains ‡3 mm were measured in 80% (12 of 15 defects) of cases treated
with PRP + ABBM and in 87% (13 of 15 defects) of cases treated with
ABBM alone. No statistically significant differences in any of the investi-
gated parameters were observed between the two groups at the 1-year
reevaluation.
Conclusions: Within the limits of the present study, it can be concluded
that 1) at 1 year after regenerative surgery with PRP + ABBM and ABBM
alone, significant PD reductions and CAL gains were found, and 2) the use
of PRP failed to improve the results obtained with ABBM alone. J Periodontol
2009;80:1599-1605.
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R
egenerative periodon-
tal therapy aims to
reconstruct the tooth-
supporting tissues (i.e., root
cementum, periodontal liga-
ment, and alveolar bone),
which have been lost due
to periodontitis or trauma.1
Polypeptide growth factors
have been shown to play a
crucial role in the growth
and differentiation of cells in-
volved in periodontal wound




BB (rhPDGF-BB) on a
beta-tricalcium phosphate
(b-TCP) vehicle or com-
bined with demineralized
freeze-dried bone allograft





trials11,12 have shown that
regenerative periodontal sur-
gery using rhPDGF-BB and
recombinant human insu-
lin-like growth factor-I or
rhPDGF-BB on a b-TCP ve-
hicle resulted in significantly
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higher improvements in terms of defect fill and gain
of clinical attachment level (CAL) compared to con-
trols (i.e., surgery and application of the vehicle or
surgery alone). Platelet-rich plasma (PRP) is an
autologous volume of plasma with a four- to five-fold
increased platelet concentration above baseline and
a well-documented source of growth factors, which
has been used to improve wound healing and to
increase the rate of bone deposition and bone volume
in combination with bone grafts during bone augmen-
tation procedures.13-15 The positive effects of PRP on
bone healing could be attributed to the angiogenetic,
proliferative, and differentiating effects on osteoblasts
of transforming growth factor (TGF)-b and PDGF that
are present in PRP in high concentrations.16 PRP
combined with different grafting materials, barrier
membranes, or an enamel matrix protein derivative
has also been used in regenerative periodontal ther-
apy with varying degrees of success.17-29 In most
studies,18-20,27-29 a barrier membrane was used to
cover the defects, and thus, the effects of PRP may
have been masked by the effects of the barrier. How-
ever, the data from controlled clinical studies evalu-
ating the additional effect of PRP when used in
combination with different grafting materials are also
somewhat controversial. Although some studies21-23
have indicated significantly higher improvements in
terms of probing depth (PD) reduction and CAL when
PRP was combinedwith a grafting material, others24-26
have failed to demonstrate significant differences.
A very well-documented grafting material that is
widely used for regenerative periodontal treatment,
ridge augmentation, and sinus-floor elevation is anor-
ganic bovine bone mineral (ABBM).30-37 Human his-
tologic studies31,37 have provided evidence for
periodontal regeneration following treatment of in-
trabony defects with ABBM alone. In intrabony de-
fects, treatment with ABBM or DFDBA resulted in
comparable clinical outcomes.32 Thus, due to its ex-
cellent biologic properties and the human histologic
evidence suggesting a potential for promoting peri-
odontal wound healing and regeneration, ABBM is
one of the most frequently used grafting materials in
reconstructive periodontal surgery.30-37 However, at
present, there are still limited data on the potential ef-
fects of PRP used in combination with ABBM.
Thus, the aim of this prospective controlled, clinical
study was to compare the healing of intrabony defects




Thirty patients (21 females and nine males; age
range: 28 to 65 years) were included in this study.
There were no differences in the age distribution
between the two groups. All patients suffered from
generalized severe chronic periodontal disease.38
Chronic periodontitis was classified as generalized
when >30% of sites were affected by a clinical attach-
ment loss ‡5 mm.38 The study had a parallel-arm
design including two treatment groups. Fifteen pa-
tients were recruited in each group (i.e., test and con-
trol groups) after having signed an informed consent.
The study was performed in accordance with the
Helsinki Declaration of 1975, as revised in 2000.
The study protocol was reviewed and approved by
the ethical board at Semmelweis University. All pa-
tients were treated at the Department of Periodontol-
ogy, Semmelweis University, by the same experienced
surgeon (FD) between June 2006 and May 2007.
The enrolled patients met the following inclusion
criteria: 1) no systemic diseases which could influ-
ence the outcome of the therapy; 2) a good level of
oral hygiene (plaque index [PI] <1);39 3) compliance
with the maintenance program; 4) presence of one in-
trabony defect with PD ‡6 mm and an intrabony com-
ponent (INTRA) ‡3 mm as detected on radiographs
and measured at bone sounding; 5) no intrabony de-
fects extending into a furcation area; and 6) no teeth
presenting furcation involvements. None of the pa-
tients were a smoker.40 The following clinical param-
eters were assessed 1 week prior to and 1 year after
the surgical procedure using the same type of peri-
odontal probe:i PI,39 gingival index (GI),39 bleeding
on probing (BOP) assessed dichotomously, PD, gingi-
val recession (GR), and CAL. The measurements
were made at six sites per tooth (mesio-facial, mid-fa-
cial, disto-facial, mesio-lingual, mid-lingual, and
disto-lingual) by a calibrated investigator (IG). The
examiner was not aware of the type of treatment ren-
dered. The cemento-enamel junction (CEJ) was used
as the reference point. In cases where the CEJ was not
visible, a restoration margin was used for these mea-
surements. Pre- and postoperative non-standardized
radiographs were taken with the long-cone parallel
technique. Additionally, in all cases, the precise posi-
tion of the periodontal probe was recorded using intra-
oral photographs taken at the same magnification and
from the same position. The deepest point of baseline
defects was included in the calculations.
Randomization
Using a randomized block approach, the defects were
randomly assigned before surgery to the two treat-
ment groups. Blocking to control for the effects of
the prognostic variables, the distance from the alveo-
lar bone crest to the bottom of the defect (INTRA) and
CAL were used to decrease outcome variability.41 The
INTRA was estimated before surgery based on radio-
graphs and transgingival bone-sounding recordings
i UNC-15, Hu-Friedy, Chicago, IL.
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by the same calibrated investigator (IG) who also per-
formed all other clinical measurements.
Intraexaminer Reproducibility
Five patients, each showing 10 teeth (single and
multi-rooted) with PDs >6 mm on at least one aspect
of each tooth, were used to calibrate the examiner.
The examiner evaluated the patients on two separate
occasions, 48 hours apart. Calibration was accepted if
>90% of the recordings could be reproduced within a
1.0-mm difference.
PRP Preparation
The PRP preparation was performed by using a stan-
dardized kit¶ immediately prior to surgery. The em-
ployed system consists of a standard laboratory
centrifuge with eight monovettes, a shaker, and a
kit with disposable material. One monovette was
filled with 8.5 ml solution (8 ml blood and 0.5 ml
citrate-phosphate-dextrose-adenine solution for anti-
coagulation). The first spin was performed at 2,400
revolutions per minute (rpm) for 10 minutes. This pro-
cedure divided the blood into three basic components:
red blood cells, PRP, and platelet-poor plasma (PPP).
The red blood cell layer formed at the lowest level, the
PRP layer formed in the middle, and the PPP layer
formed at the top. PRP and PPP were collected in a sec-
ond monovette. A second spin was performed at
3,600 rpm for 15 minutes The platelet pellet concen-
trated at the bottom of the monovette, whereas the
PPP concentrated on the top. The PPP was removed
so that only PRP remained in the monovette. After re-
suspending the platelet pellet within the remaining
volume of plasma in the shaker, a 0.4-ml volume of
PRP was produced.
Surgical Procedure
Following local anesthesia, intracrevicular incisions
were made, and mucoperiosteal flaps were raised ves-
tibularly and orally. For better access to the surgical
site or to achieve better closure, the flap was extended
one or two teeth mesially or distally in most cases.
Vertical releasing incisions were performed when
deemed necessary. The granulation tissue was re-
moved from the defects, and the roots were thor-
oughly scaled and planed by means of hand and
ultrasonic instruments. No conditioning of the root
surfaces was performed. During surgery, the following
measurements were made: the distance from the CEJ
to the bottom of the defect (CEJ-BD) and the distance
from the CEJ to the most coronal extension of the al-
veolar bone crest (CEJ-BC). The INTRA of the defects
was defined as CEJ-BD – CEJ-BC.
In the test group (PRP + ABBM), at the time of ap-
plication, PRP was first activated after combination
with an equal volume of a sterile saline solution con-
taining 10% calcium chloride and 100 U/ml sterile
thrombin. Within a few seconds, the PRP displayed
a sticky consistency. Afterwards, ABBM# granules
(particle size, 0.25 to 1.0 mm) were mixed with the co-
agulated PRP. Care was taken not to overfill the de-
fects. The same surgical protocol was also used for
the control sites (ABBM alone) with the exception of
using PRP. Finally, the flaps were coronally advanced
and closed with vertical or horizontal mattress su-
tures.
Postoperative Care
All patients received antibiotics for 1 week (3 · 500
mg amoxicillin/day). Postoperative care consisted
of 0.2% chlorhexidine rinses twice a day for 4 weeks.
Sutures were removed 14 days after the surgery. Re-
call appointments were scheduled weekly during the
first 6 weeks after surgery and once per month follow-
ing the rest of the observation period of 1 year. The re-
call appointments mainly consisted of reinforcement
of oral hygiene measures and professional supragin-
gival tooth cleaning.
Statistical Analyses
Statistical analyses were performed using a commer-
cially available software program.**
The primary outcome variable was CAL. For the
statistical evaluation of the changes from baseline
to 1 year in each treatment group, the paired t test
was used. For the comparisons between the groups,
the unpaired t test was used. The a error was set at
0.05. The power of the study, given ‡1 mm as a sig-
nificant difference between the groups, was calcu-
lated to be 0.80.
RESULTS
The postoperative healing was uneventful in all cases.
No complications, such as allergic reactions, ab-
scesses, or infections, were observed throughout the
study period. All patients complied with the monthly
recall appointments throughout the 1-year study pe-
riod. No dropouts occurred.
There were minor differences in the gender distribu-
tion between the groups (i.e., five males in the test
group and four males in control group). Table 1 illus-
trates the mean PI, GI, and BOP for both groups. GI
and BOP improved statistically significantly com-
pared to baseline, but no statistically significant differ-
ences were found between the two groups.
The defects displayed a comparable distribution
and configuration in the two groups (Table 2). The
depth of the INTRA as measured during surgery is
presented in Table 3. There were no differences in
the depth of the INTRA between the two groups.
¶ Curasan PRP kit, Curasan, Kleinostheim, Germany.
# Bio-Oss, Geistlich, Wolhusen, Switzerland.
** SPSS for Windows (2003), SPSS, Chicago, IL.
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At baseline, no statistically significant differences
were found between the two groups for mean PD,
GR, and CAL (Table 4). At 1 year, mean PD decreased
significantly in both groups (P <0.001) compared to
baseline, but no statistically significant difference be-
tween the groups was found (Table 4). Mean GR in-
creased significantly, in both groups (P <0.01)
compared to baseline, but no statistically significant
difference between the groups was found (Table 4).
In both groups, mean CAL improved significantly
compared to baseline (P<0.001) without a statistically
significant difference between the groups (Table 4).
At baseline, the mean GR was 1.3 – 1.1 mm in the
PRP + ABBM group and 1.1 – 0.9 mm in the ABBM
group, with no statistically significant difference be-
tween the groups (Table 4). At 1 year, the mean GR
measured 1.9 – 1.8 mm in the ABBM + PRP group
and 1.7 – 1.5 mm in the ABBM group. Compared to
baseline, the changes in GR were statistically signifi-
cant for both groups (P <0.01) without a statistically
significant difference between the groups.
At baseline, the mean CAL was 9.9 – 1.7 mm in the
PRP + ABBM group and 9.6 – 1.9 mm in the ABBM
group. No statistically significant difference was found
between the groups. At 1 year, the mean CAL was 5.3 –
1.8 mm in the PRP + ABBM group and 4.9 – 1.5 mm in
the ABBM group (Table 4). Mean CAL gain was 4.6 –
1.7 mm in the PRP + ABBM group and 4.7 – 1.6 mm in
the ABBM group. In both groups, CAL improved signif-
icantly compared to baseline (P <0.001) without a sta-
tistically significant difference between the groups.
At 1 year, CAL gains ‡3 mm were measured in
80% (12 of 15 defects) of the cases treated with
PRP + ABBM and 87% (13 of 15 defects) of the cases
treated with ABBM alone.
DISCUSSION
The results of the present study indicated that signif-
icant clinical improvements can be obtained in deep
intrabony defects following treatment with PRP +
ABBM and ABBM alone. However, no significant dif-
ferences in any of the investigated parameters were
found between the two treatments. The observation
that all used materials were very well tolerated without
any signs of allergic reactions, flap necrosis, or rejec-
tion of the implanted materials is in line with previous
reports.17-37,42,43 The finding that regenerative sur-
gery with PRP +ABBM may result in significant clinical
improvements corroborates previously published
data.20,21 In a controlled clinical study21 using a com-
parable design to that employed in the present trial, at
6 months following surgery, both approaches yielded
significant clinical improvements compared to base-
line, although the PRP enhanced group resulted in sig-
nificantly higher outcomes in terms of PD reduction
and CAL gain compared to those obtained with the
graft alone. In that study, mean CAL gain measured
3.15 mm in the PRP + ABBM group and 2.31 mm in
the ABBM group, respectively, whereas CAL gains
‡3 mm were obtained in 77% of the PRP enhanced
group versus 38.8% in the group treated with the graft
alone.21 These values are lower compared to those
obtained in the present study, where mean CAL gain
measured 4.6 – 1.7 mm in the PRP +ABBM group and
4.7 – 1.6 mm in the ABBM group, whereas CAL gains
‡3 mm were obtained in 80% of the defects treated
with PRP + ABBM and 87% of the defects treated with
ABBM alone. Possible explanations for this discrep-
ancy might be related to differences in terms of study
design, initial defect depth, and intrabony defect
Table 1.






(n = 15) P Value
PI (mean – SD)
Baseline 0.8 – 0.1 0.7 – 0.1 NS
1 year 0.7 – 0.2 0.6 – 0.2 NS
P value NS NS
GI (mean – SD)
Baseline 1.2 – 0.2 1.3 – 0.3 NS
1 year 0.6 – 0.1 0.7 – 0.4 NS
P value <0.05 <0.05
BOP (%)
Baseline 43 42 NS
1 year 15 13 NS
P value <0.05 <0.05
NS = not statistically significant.
Table 2.









Anterior teeth 0 2
Premolars 4 3
Molars 11 10
Combined 1- and 2-wall 9 9
2-wall 6 6
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configuration.44-46 Recent findings45,46 have also in-
dicated that contained type defects (i.e., 3-wall or
narrow and deep defects) may provide a better envi-
ronment for enhancing blood-clot stability compared
to non-contained type defects (defects with missing
bony walls or supraalveolar type defects), thus signif-
icantly influencing the outcomes.
Differences in the results might also be related to
the study design (the present study had a parallel-
arm design, whereas the study by Hanna et al.21
was a split-mouth study and included smokers).
Moreover, the posthealing evaluation period was lon-
ger in this study compared to previous ones (i.e., 6
months)20,21 and included monthly recall appoint-
ments consisting of reinforcement of oral hygiene
measures and professional supragingival tooth clean-
ing. Because PRP may influence the early phases of
wound healing, it may be speculated that this initial
advantage might be equalized after a longer period
of time (1 year).13-16 Another possible explanation
for the differences between the reported findings
might be related to differences in the methods used
to prepare PRP.47 It
has been documented
that differences in the
level and proportion of
various growth factors
may be found between
currently available com-
mercial systems that, in
turn, may affect out-
comes.47 Alternatively,
it has been shown that
PRP volumes prepared with the technique used in this
study contain a mean platelet count value of 2,520 ·
103/ml and high mean concentration values of growth
factors (i.e., 295 ng/ml PDGF-AB and 500 ng/ml TGF-
b1).48 Furthermore, it should also be realized that the
present study did not have a statistical power to rule
out the possibility of a difference between the two
groups, and thus, a much higher number of defects
would be needed to detect an eventual difference be-
tween the treatments.49
Another aspect that should be taken into consider-
ation when discussing the present results is the lack
of a placebo instead of PRP. The use of a placebo may
be desirable to adequately evaluate the potential of
PRP, but the present study included the use of a graft-
ing material for both groups, which yielded excellent
outcomes. Thus, it seems likely that, even with the
use of a placebo, the detection of significant differ-
ences between the two groups might have been dif-
ficult.
The positive outcomes obtained with ABBM alone
are in line with findings from previous studies32,42,43
that have failed to demonstrate significant differences
between treatment with ABBM alone versus DFDBA
alone or a combination of an enamel matrix derivative
and ABBM. These results seem to indicate that, at
least from a clinical point of view, treatment with
PRP +ABBM may not significantly improve the results
obtained with ABBM alone. When interpreting the re-
sults obtained in the PRP + ABBM group, it should be
kept in mind that the precise mechanism of PRP on
periodontal regeneration is still not well understood,
and until now, there is no evidence demonstrating
periodontal regeneration in human intrabony defects
following this approach. In this context, findings from
human histologic case reports have also provided ev-
idence of cementum, periodontal ligament, and bone
formation following treatment with ABBM alone.31,37
Thus, the clinical improvements obtained with ABBM
alone may represent a clinical improvement and, at
least to some extent, a regenerative type of healing.
Conversely, the present results need to be interpreted
with caution because the possibility for PRP to show
any beneficial effect when used in combination with
ABBM might have been masked due to the fact that
Table 3.
Baseline Defect Characteristics (mm; mean – SD)
Treatment PD CAL CEJ-BD CEJ-BC INTRA
PRP + ABBM (n = 15) 8.6 – 1.8 9.9 – 1.7 11.0 – 1.8 5.9 – 1.7 5.1 – 1.7
ABBM (n = 15) 8.5 – 2.0 9.6 – 1.9 10.8 – 2.0 5.8 – 1.8 5.0 – 1.9
P value NS NS NS NS NS
NS = not statistically significant.
Table 4.
Clinical Parameters (mm; mean – SD) at
Baseline and 1 Year (n = 15 for each group)
Clinical
Parameter Baseline 1 Year Difference P Value
PD
PRP + ABBM 8.6 – 1.8 3.4 – 1.4 5.2 – 1.6 <0.001
ABBM 8.5 – 2.0 3.2 – 1.3 5.3 – 1.7 <0.001
P value NS NS NS
GR
PRP + ABBM 1.3 – 1.1 1.9 – 1.8 0.6 – 1.7 <0.01
ABBM 1.1 – 0.9 1.7 – 1.5 0.6 – 1.6 <0.01
P value NS NS NS
CAL
PRP + ABBM 9.9 – 1.7 5.3 – 1.8 4.6 – 1.7 <0.001
ABBM 9.6 – 1.9 4.9 – 1.5 4.7 – 1.6 <0.001
P value NS NS NS
NS = not statistically significant.
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treatment with ABBM alone resulted in significant im-
provements.
CONCLUSIONS
Within its limits, the present study showed that 1) sig-
nificant PD reductions and CAL gains were found
1 year after regenerative surgery with PRP + ABBM
and ABBM alone, and 2) the use of PRP failed to im-
prove the results obtained with ABBM alone.
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